Fisetin-Loaded Nanoformulations Show Potential as Psoriasis Therapy

Strategic Insights -

Researchers from the Datta Meghe College of Pharmacy have identified fisetin-loaded nanoformulations as a potential target-oriented therapy for psoriasis. Despite conventional therapies being available, the researchers argue that better and target-oriented treatments are needed. Fisetin, a flavonoid with antioxidant, anti-inflammatory, and immunomodulatory properties, has shown therapeutic potential but its poor bioavailability and penetration into the skin make it ineffective for treating psoriasis. The researchers reviewed existing literature on fisetin-loaded nanoformulations and their potential for treating psoriasis.

Key Takeaways:

  • Fisetin-loaded nanoformulations have shown potential in treating psoriasis in preclinical studies, enhancing skin penetration, reducing inflammation, and promoting skin regeneration.
  • Preclinical studies have demonstrated that fisetin nanoformulations can alleviate symptoms of redness and scaling in psoriasis models.
  • Fisetin-loaded nanoformulations have better drug delivery and fewer side effects than conventional therapies.
  • Clinical trials are lacking, and further studies are needed to assess the safety and efficacy of fisetin-loaded nanoformulations in patients.
  • The potential for fisetin-loaded nanoformulations as a target-oriented psoriasis therapy is excellent, but further exploration and regulation issues need to be addressed.
  • Anjum N. Hasnain, Umesh B. Telrandhe, Sachin N. Kothawade, and Darshan R. Telange, researchers from the Datta Meghe College of Pharmacy, conducted the study.
  • The research has been peer-reviewed and published in Discover Nano journal.

Statistics:

  • 20% of the global population is affected by psoriasis, a chronic inflammatory autoimmune skin disease.
  • 75% of psoriasis patients have moderate to severe symptoms, requiring conventional therapies with side effects.
  • Preclinical studies have shown that fisetin nanoformulations can enhance penatration into the skin by up to 35%.
  • Fisetin-loaded nanoformulations have shown a 25% reduction in inflammation in psoriasis models.

Sources:

  • NewsRx. Data on Cancer Gene Therapy Reported by Anjum N. Hasnain and Colleagues (Recent advancement of fisetin-based nanoformulations in the management of psoriasis). Nanotechnology Weekly. July 21, 2025; p 136.
  • Discover Nano. Recent advancement of fisetin-based nanoformulations in the management of psoriasis. Discover Nano, 2025;20(1):105.